SG11202000055PA - Antibodies that modulate a biological activity expressed by a cell - Google Patents

Antibodies that modulate a biological activity expressed by a cell

Info

Publication number
SG11202000055PA
SG11202000055PA SG11202000055PA SG11202000055PA SG11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA
Authority
SG
Singapore
Prior art keywords
utrecht
yalelaan
international
cell
bind
Prior art date
Application number
SG11202000055PA
Inventor
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Kruif Cornelis Adriaan De
Paulus Johannes Tacken
Mark Throsby
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202000055PA publication Critical patent/SG11202000055PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau vitivio VIII oviolo OH itio oimIE (43) International Publication Date 10 January 2019 (10.01.2019) W I PO I (10) International Publication Number WO 2019/009728 Al PCT (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) CO7K 16/12 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/NL2018/050451 (22) International Filing Date: Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Filing Language: Publication Language: Priority Data: 17180070.9 06 July 2017 (06.07.2017) EP Applicant: MERUS N.V. [NL/NL]; Yalelaan 62, 3584 CM Utrecht (NL). Inventors: GEUIJEN, Cecilia Ana Wilhelmina; c/o Yale- laan 62, 3584 CM Utrecht (NL). KLOOSTER, Rinse; c/ o Yalelaan 62, 3584 CM Utrecht (NL). DE KRUIF, Cor- nelis Adriaan; c/o Yalelaan 62, 3584 CM Utrecht (NL). TACKEN, Paulus Johannes; c/o Yalelaan 62, 3584 CM Utrecht (NL). THROSBY, Mark; c/o Yalelaan 62, 3584 CM Utrecht (NL). LOGTENBERG, Ton; c/o Yalelaan 62, 3584 CM Utrecht (NL). 06 July 2018 (06.07.2018) English English Agent: JANSEN, C.M.; V.O., Carnegieplein 5, 2517 KJ Den Haag (NL). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (25) (26) (30) (71) (72) (74) (81) (84) 1-1 GC N cr\ O O cr\ O 1-1 O (54) Title: ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL (57) : The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lympho- cyte activation 3 (LAG 3) mediated inhibition in a PD- 1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD- 1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD- 1 and a variable domain that can bind to an extracellular part of LAG3.
SG11202000055PA 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell SG11202000055PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180070 2017-07-06
PCT/NL2018/050451 WO2019009728A1 (en) 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell

Publications (1)

Publication Number Publication Date
SG11202000055PA true SG11202000055PA (en) 2020-02-27

Family

ID=59295099

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000055PA SG11202000055PA (en) 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell

Country Status (14)

Country Link
US (2) US11732043B2 (en)
EP (1) EP3649156A1 (en)
JP (1) JP2020525533A (en)
KR (1) KR20200037250A (en)
CN (1) CN111094350A (en)
AU (1) AU2018297061B2 (en)
BR (1) BR112020000228A2 (en)
CA (1) CA3068933A1 (en)
EA (1) EA202090005A1 (en)
IL (1) IL271833A (en)
PH (1) PH12020550010A1 (en)
SG (1) SG11202000055PA (en)
TW (1) TW201920275A (en)
WO (1) WO2019009728A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018127711A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single Domain Antibodies to Programmed Cell Death (PD-1)
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019179422A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/lag-3 antibody molecules
BR112020019795A2 (en) * 2018-03-30 2021-01-05 Merus N.V. MULTIVALENT ANTIBODY
EP3958900A4 (en) * 2019-04-26 2023-01-25 WuXi Biologics Ireland Limited Bispecific antibodies against pd-1 and lag-3
MX2021013646A (en) 2019-05-09 2022-01-31 Merus Nv Variant domains for multimerizing proteins and separation thereof.
US11667711B2 (en) 2020-05-27 2023-06-06 Agilent Technologies, Inc. Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
CN113416249B (en) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 Compositions against tetanus toxin
EP4019633A1 (en) * 2020-12-23 2022-06-29 Technische Universität München Conditional cell connectors
JP2024511871A (en) 2021-03-31 2024-03-15 メルス ナムローゼ フェンノートシャップ Novel multispecific antibody
WO2022211629A1 (en) 2021-03-31 2022-10-06 Merus N.V. Novel pd-1 binding domains
CA3213682A1 (en) 2021-03-31 2022-10-06 Simon Edward PLYTE Multispecific binding moieties comprising novel pd-1 binding domains
WO2024072893A1 (en) * 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
SI1523496T1 (en) 2002-07-18 2011-11-30 Merus B V Recombinant production of mixtures of antibodies
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
MX2010014542A (en) 2008-06-27 2011-04-05 Merus B V Antibody producing non-human mammals.
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
HUE037651T2 (en) 2011-04-20 2018-09-28 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
WO2013022091A1 (en) 2011-08-11 2013-02-14 小野薬品工業株式会社 Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EA035344B1 (en) 2012-04-20 2020-05-29 Мерюс Н.В. Method for producing two antibodies from a single host cell
HUE042040T2 (en) * 2012-09-27 2019-06-28 Merus Nv Bispecific igg antibodies as t cell engagers
KR20220126813A (en) * 2014-03-14 2022-09-16 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016011069A1 (en) 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
JO3663B1 (en) * 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
JP6974311B2 (en) * 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター New PD-1 immunomodulator
KR20180093127A (en) * 2015-07-30 2018-08-20 마크로제닉스, 인크. PD-1-Binding Molecules and Methods of Use Thereof
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
WO2017049143A1 (en) 2015-09-18 2017-03-23 Dana-Farber Cancer Institute, Inc. Methods of reducing liver pd-1-expressing cd8+t cells using pd-1 fc fusion proteins that bind fc receptors
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
EP3912998A3 (en) * 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
AU2016355570B2 (en) * 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
JP6929951B2 (en) * 2017-02-22 2021-09-01 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド Anti-LAG-3 antibody and its use
CN110366546A (en) 2017-03-01 2019-10-22 氟化学有限公司法兰克福 The savings medium of new material and its manufacture to be used as in sensitive energy-storage system within the scope of low, medium and high temperature
DE202017102208U1 (en) 2017-03-03 2018-03-07 Sarah Yanik Composition, in particular for the treatment of hoof and claw diseases in animals, and their production
AU2018297058B2 (en) * 2017-07-06 2021-04-29 Merus N.V. Bispecific anti PD1-anti TIM3 antibodies
US11667714B2 (en) * 2017-07-06 2023-06-06 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2020167122A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Producing compositions comprising two or more antibodies.
EP4157354A1 (en) 2020-05-27 2023-04-05 Dana-Farber Cancer Institute, Inc. Bispecific molecules for selectively modulating t cells

Also Published As

Publication number Publication date
WO2019009728A8 (en) 2020-01-09
AU2018297061B2 (en) 2021-05-06
BR112020000228A2 (en) 2020-07-14
EP3649156A1 (en) 2020-05-13
US20200216540A1 (en) 2020-07-09
PH12020550010A1 (en) 2020-10-12
CN111094350A (en) 2020-05-01
US20230406932A1 (en) 2023-12-21
TW201920275A (en) 2019-06-01
US11732043B2 (en) 2023-08-22
CA3068933A1 (en) 2019-01-10
EA202090005A1 (en) 2020-06-18
WO2019009728A1 (en) 2019-01-10
JP2020525533A (en) 2020-08-27
IL271833A (en) 2020-02-27
AU2018297061A1 (en) 2020-01-30
KR20200037250A (en) 2020-04-08

Similar Documents

Publication Publication Date Title
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201811184UA (en) Lag -3 binding members
SG11201908088RA (en) Antibodies against pd-l1
SG11201909949XA (en) Targeted immunotolerance
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof